Temporary interruption of endocrine therapy in women with endocrine-responsive breast cancer did not affect cancer outcomes
1. The 3-year incidence of breast cancer in the study group was 8.9% compared to 9.2% in the control group ...
Tag: endocrine therapy
#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Adjuvant ibandronate does not improve survival in postmenopausal patients with ER⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer
Click to read the study in The Lancet Oncology.